Evolent Health Secures “Moderate Buy” Rating from Analysts

Shares of Evolent Health, Inc. (NYSE: EVH) have garnered an average rating of “Moderate Buy” from sixteen brokerage firms monitoring the company, as reported by MarketBeat Ratings. Among these analysts, one has assigned a sell rating, one a hold rating, while the remaining fourteen have recommended buying the stock. The consensus twelve-month target price set by analysts stands at $10.71.

In recent evaluations, various equities research analysts have provided insights on Evolent Health’s stock. Citizens JMP recently adjusted its target price from $11.00 to $10.00, maintaining a “market outperform” rating. Meanwhile, Stephens upgraded the stock from an “equal weight” rating to an “overweight” rating, establishing a price objective of $7.00. On the other hand, BTIG Research lowered its target price from $20.00 to $16.00, while maintaining a “buy” rating. Oppenheimer also reduced its price target from $18.00 to $12.00, citing an “outperform” rating. Lastly, Citigroup cut its target from $9.50 to $6.00, but kept a “buy” rating.

Earnings Report Highlights

Evolent Health released its quarterly earnings on June 4, 2023, revealing an earnings per share (EPS) of $0.21 for the quarter, alongside revenues amounting to $427.70 million. The company reported a positive return on equity of 1.79%, but noted a negative net margin of 6.24%. Analysts project that Evolent Health will post an EPS of $0.08 for the current fiscal year.

In related developments, Brendan B. Springstubb, a director at Evolent Health, purchased 10,000 shares on November 18, 2023, at an average price of $3.82 per share. This transaction, valued at $38,200, has increased his ownership in the company by 20.48%, bringing his total shares to 58,821, worth approximately $224,696.22. The transaction was disclosed in a filing with the Securities and Exchange Commission.

Institutional Investors Take Notice

Recent activity from institutional investors indicates growing interest in Evolent Health. Nisa Investment Advisors LLC increased its holdings by 88.0% during the second quarter, now owning 2,551 shares worth $29,000 after acquiring an additional 1,194 shares. Similarly, CIBC Private Wealth Group LLC expanded its position by 4,000.0% in the third quarter, securing 4,100 shares valued at $35,000.

Other notable institutional shifts include Parallel Advisors LLC, which increased its stake by 82.6% during the second quarter, and Strs Ohio, which acquired a new stake valued at approximately $47,000 in the first quarter. Additionally, Pilgrim Partners Asia Pte Ltd entered the market with a new stake worth around $51,000 during the third quarter.

Evolent Health, headquartered in Arlington, Virginia, is a healthcare technology and services company established in 2011 as a collaboration between TPG and the University of Pittsburgh Medical Center (UPMC). The firm supports health systems, physician organizations, and health plans in transitioning from traditional fee-for-service models to value-based care arrangements, utilizing its proprietary technology and clinical expertise.

As Evolent Health continues to attract investor interest and receive positive ratings, its strategic initiatives in healthcare technology may position it well for future growth.